TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025

Reuters

2025/10/21

TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025

TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase (CDK) inhibitor candidates: TYK-00540 (CDK2/4 inhibitor), TY-2699a (CDK7 inhibitor), and TY-302 (CDK4/6 inhibitor). The data were presented as posters at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on October 21, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577820680"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577820680\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577820680?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577820680","market":"nz","top_or_hot":-1,"title":"TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase (CDK) inhibitor candidates: TYK-00540 (CDK2/4 inhibitor), TY-2699a (CDK7 inhibitor), and TY-302 (CDK4/6 inhibitor). The data were presented as posters at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-21 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase (CDK) inhibitor candidates: TYK-00540 (CDK2/4 inhibitor), TY-2699a (CDK7 inhibitor), and TY-302 (CDK4/6 inhibitor). The data were presented as posters at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02410","symbol_name":"同源康医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL7sF17S:1","article_id":"2577820680","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577820680","pubTimestamp":1761048917,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase  inhibitor candidates: TYK-00540 , TY-2699a , and TY-302 . The data were presented as posters at the European Society for Medical Oncology  Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original cont","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02410":"同源康医药-B","BK1161":"生物科技"},"translate_title":"TYK Medicines在ESMO 2025上公布CDK抑制剂积极的早期临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":0.9},"content_text":"TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025\n    \n\n        TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase (CDK) inhibitor candidates: TYK-00540 (CDK2/4 inhibitor), TY-2699a (CDK7 inhibitor), and TY-302 (CDK4/6 inhibitor). The data were presented as posters at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on October 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}